Lazaro Cebas Andrea, Cortijo Cascajares Susana, Pablos Bravo Siria, Del Puy Goyache Goñi Maria, Gonzalez Monterrubio Gema, Perez Cardenas Maria Dolores, Ferrari Piquero Jose Miguel
Pharmacy Service, Hospital Universitario 12 de Octubre, Madrid, Spain.
J BUON. 2017 Mar-Apr;22(2):334-339.
To investigate the preference of HER2+ breast cancer patients and nursing professionals for subcutaneous (SC) versus intravenous (IV) trastuzumab and to evaluate the financial impact derived from the use of the SC formulation.
A cross-sectional questionnaire-based study was carried out to investigate preferences of all patients who started treatment with SC trastuzumab while they had received the IV formulation before. The preference of nursing staff in charge of preparation and administration was also analysed. The financial impact was evaluated considering the number of preparations of SC trastuzumab and the cost of IV and SC trastuzumab, the consumables used for preparation and administration and nursing staff time for preparation.
76 female patients were included, 84% completed the questionnaire. Of the patients, 94% declared to be satisfied with the SC route and 88% would prefer SC administration if they had to choose between IV and SC. Time saving was the main reason to justify satisfaction and preference (48 and 45% respectively). The most common adverse event related to SC trastuzumab was post-injection pain in the injection site, experienced by 77% of the patients. SC trastuzumab was preferred by 100% of the nursing staff. Total annual savings using SC formulation instead of the IV were 35.332€.
SC trastuzumab is preferred by patients and the nursing staff versus the IV administration. The use of SC trastuzumab reduced the cost derived from trastuzumab administration.
调查HER2+乳腺癌患者和护理专业人员对皮下注射（SC）与静脉注射（IV）曲妥珠单抗的偏好，并评估使用皮下注射制剂所产生的财务影响。
开展了一项基于问卷调查的横断面研究，以调查所有曾接受过静脉注射制剂治疗，而后开始皮下注射曲妥珠单抗治疗的患者的偏好。同时分析负责配制和给药的护理人员的偏好。考虑皮下注射曲妥珠单抗的配制数量、静脉注射和皮下注射曲妥珠单抗的成本、配制和给药所用耗材以及护理人员的配制时间，评估财务影响。
纳入76例女性患者，84%完成了问卷。其中，94%的患者表示对皮下注射途径满意，88%的患者表示如果必须在静脉注射和皮下注射之间选择，会更喜欢皮下注射。节省时间是表明满意和偏好的主要原因（分别为48%和45%）。与皮下注射曲妥珠单抗相关的最常见不良事件是注射部位注射后疼痛，77%的患者有此经历。100%的护理人员更喜欢皮下注射曲妥珠单抗。使用皮下注射制剂而非静脉注射制剂，每年可节省35332欧元。
与静脉注射相比，患者和护理人员更喜欢皮下注射曲妥珠单抗。使用皮下注射曲妥珠单抗降低了曲妥珠单抗给药的成本。
